By embracing diversity in #ClinicalTrials, we enable more equitable and inclusive healthcare. How can this be achieved? Swipe right to learn more.
Boehringer Ingelheim
Fabrication de produits pharmaceutiques
Ingelheim am Rhein, Rhineland-Palatinate 1 808 630 abonnés
À propos
Concevoir des médicaments encore plus efficaces pour les humains et les animaux est au cœur de notre action. Notre mission est de créer des thérapies innovantes qui ont le potentiel de changer la vie des patients. Depuis sa création en 1885, Boehringer Ingelheim est une entreprise familiale et indépendante. Nous avons la liberté de poursuivre notre propre vision à long terme, de nous tourner vers l’avenir pour identifier les enjeux de santé de demain et de concentrer nos efforts dans les domaines où nous pouvons apporter une réelle contribution. Nous sommes fiers de concourir à l’indépendance sanitaire française et européenne grâce à plus de 26 000 collaborateurs en Europe. Engagés dans l’élaboration et la fabrication de médicaments ‘‘made in Europe’’, plus de 78 % de nos traitements en santé humaine mis à disposition des patients français sont intégralement produits en Europe, y compris leurs principes actifs. Notre vision pour Boehringer Ingelheim en France : En France, Boehringer Ingelheim est présent sur 9 sites, au travers d’activités de recherche et développement, de production et la mise à disposition de produits de santé humaine et animale. Grâce à notre histoire, notre empreinte et nos expertises, nous avons l’ambition de prendre un temps d’avance, en devenant un champion européen qui s’appuie sur une approche globale de la santé, au carrefour des enjeux indissociables de la santé humaine et de la santé animale. En France, 2 362 collaborateurs créent quotidiennement de la valeur par l’innovation (2 096 en santé animale et 266 en santé humaine) et développent une culture diversifiée, collaborative et inclusive. Nous pensons qu’assurer le développement de nos collaborateurs c’est assurer le développement de notre entreprise. Rejoindre Boehringer Ingelheim, c’est travailler avec des équipes intègres et passionnées qui agissent avec respect, confiance et empathie pour progresser ensemble. En savoir plus sur https://www.boehringer-ingelheim.fr/
- Site web
-
http://www.boehringer-ingelheim.com
Lien externe pour Boehringer Ingelheim
- Secteur
- Fabrication de produits pharmaceutiques
- Taille de l’entreprise
- de 10 000 employés
- Siège social
- Ingelheim am Rhein, Rhineland-Palatinate
- Type
- Société civile/Société commerciale/Autres types de sociétés
- Domaines
- Pharmaceuticals, Animal Health, Innovation, Research, Health Care, Improve Health, Biopharmaceuticals et Contract Manufacturing
Lieux
Employés chez Boehringer Ingelheim
-
Gwen Whitfield Foster
-
Thomas Macauley
Research Data Management - Lab Services Engineer at Boehringer-Ingelheim
-
Mitchell Taub
Highly Distinguished Research Fellow
-
Ralf Schundelmeier
Product Leader (ex Salesforce) - Building Platforms for Applications, GenAI / Machine Learning & Data
Nouvelles
-
We're not only driving innovation ourselves, we're also sharing open source technologies and device development knowledge with others. In order to improve retinal health monitoring we're sharing our software and to best involve patients in device development we provide our blueprint. Want to know more about our approach? Explore here: https://bit.ly/3XicGXt #PatientCentricity #HealthcareInnovation #KnowledgeSharing
-
#NEWS: The German Vice Chancellor and Federal Minister of Economics Robert Habeck visited our new biomass power plant in Ingelheim today. By using renewable sources, the plant supplies up to 95% of our site's energy needs. This will save around 50,000 tons of CO₂ per year in the future. Learn more about the inauguration and our #sustainability goals: https://bit.ly/3S1dtIS #GreenEnergy
-
-
Disparities in clinical trials must become a thing of the past. Inclusion of race, sex, age, genetics, demographics and geographies in clinical trial designs allows us to achieve relevant healthcare solutions that meet the needs of diverse patient populations. Read more here: https://lnkd.in/erYSU5db #ClinicalTrials #Diversity
-
-
#NEWS: Our first-in-class SIRPα immuno-oncology program, initiated by OSE Immunotherapeutics, is moving to the next phase in clinical development. Based on the positive data from our first clinical studies and the switch to an improved antibody we aim to provide innovative immuno-oncology treatments to the benefit of more people. Learn more: https://bit.ly/4cHPzd8 #Cancer #ImmunoOncology #ResearchAndDevelopment
-
-
“Vision is more than just a function, it’s the sense that people most value, it connects individuals to their way of life.” Read more from our Director of Cardio-Metabolic Diseases Research/Retinal Health, Remko Bakker, as he reflects on our research and development program in #RetinalHealth 👉 https://lnkd.in/eb5YN9Pj
-
-
It's essential to raise awareness of the impact that diseases like generalized pustular psoriasis (#GPP) have on people's lives. By collaborating with patient organizations like IFPA, we aim to support their efforts to empower people living with GPP.
Generalized Pustular Psoriasis #GPP is a rare, severe form of #psoriaticdisease. Today Emmylou Casanova shared her experience navigating painful symptoms and finding a diagnosis. On stage with Prof Ricardo Romiti who stressed the need for continuous patient care. Register to watch online: https://lnkd.in/dRJDbMMh. Presented by Boehringer Ingelheim at #IFPAConference2024.
-
-
#HCP: Tango is a dance in which 2 people communicate through their movements. In the same way, it also takes 2 tests to get the full picture about #ChronicKidneyDisease (CKD). Follow clinical guidelines from diabetes and kidney organizations and issue 2 tests – an eGFR (blood) and UACR (urine) test. Learn more here: https://lnkd.in/eHhyKVMc
-
-
Together with the Advisory Board on Cat Diseases (ABCD) we proudly recognize Dr. Katharina Zwicklbauer (Ludwig-Maximilians-Universität München) with the 2024 Young Scientist Award. Katharina's research on feline infectious peritonitis (FIP), a fatal disease caused by a feline coronavirus, that mostly affects young cats, made important contributions to the field of feline medicine. Just three years ago, there were no treatment options available. Now, there is a whole new product class that we still need to fully explore. In her controlled study, Katharina evaluated different oral formulations of these new antivirals and showed promising results on the clinical evolution and virological parameters. #LifeForward
-
-
#NEWS: We're launching the Phase 1 study of BI 3034701, a potential first-in-class, triple agonist obesity treatment developed in our partnership with Gubra. Discover how we are advancing our comprehensive strategy at https://bit.ly/4blrbNu #CardioMetabolic #ResearchCollaboration #Innovation
-